Innovation at Glenmark is driven by a clear purpose: to advance differentiated, science-led therapies that address health conditions and deliver meaningful benefit to patients. Our innovative portfolio is concentrated across Respiratory, Dermatology, and Oncology -the therapeutic areas where medical need is significant, science is evolving rapidly, and Glenmark has built deep clinical and development expertise.
Our approach to innovation is defined by therapeutic focus, scientific rigor, and global partnerships. By advancing novel and specialty therapies with clear clinical relevance, we aim to improve outcomes while strengthening Glenmark’s position as a global, innovation-led pharmaceutical company.
Oncology - Next-Generation Therapies with Differentiated Science
Our Oncology portfolio is focused on advancing differentiated, science-led therapies across solid tumors and hematological malignancies, where disease complexity and unmet medical need continue to challenge existing treatment options. The approach combines deep disease understanding, disciplined science, and global partnerships to support the development of differentiated therapies with meaningful clinical relevance.
Our capabilities are strengthened through Ichnos Glenmark Innovation (IGI), which contributes specialised expertise in biologics discovery and early development within the broader oncology ecosystem. A flagship programme within this portfolio is ISB 2001, a first-in-class trispecific antibody being developed for the treatment of multiple myeloma. The programme is currently in early clinical development and is being advanced through a global partnership with AbbVie, providing strong external validation of the underlying science and approach.
Complementing biologic innovation, the oncology portfolio also includes advanced immunotherapies and targeted treatments developed through strategic global partnerships. These include Envafolimab (QinHayo®), Tislelizumab (TEVIMBRA®), Zanubrutinib (Brukinsa®), Trastuzumab Rezetecan (SHR-A1811), a next-generation HER2-targeting antibody drug conjugate (ADC), Aumolertinib – a Third-Generation EGFR-TKI, among others.
Together, these partnerships expand access to advanced immunotherapies, targeted treatments, and emerging modalities such as antibody–drug conjugates (ADCs), enabling a broader and more differentiated oncology offering across solid tumours and hematological malignancies.
Our footprint in Oncology reflects the convergence of science, collaborations and purpose –
backed by longstanding R&D, a diversified portfolio, and partnerships that expand global reach.
2
Decades of research in cancer care
5
Strategic collaborations
Respiratory - Advancing Care Across Allergic and Airway Diseases
Our portfolio spans the full continuum covering chronic conditions such as asthma, COPD, interstitial lung disease (ILD) and everyday conditions like cough, rhinitis, and allergies.
We offer one of the industry’s most advanced devices from Dry Powder Inhalers (DPI), Metered Dose Inhalers (MDI), to nasal sprays and nebulisation. We are driving the Respiratory franchise forward by building next-generation products, robust delivery systems, and nebulisation therapies for ease of use and better patient outcomes.
A key innovation in this area is Ryaltris®, a differentiated fixed-dose nasal spray that combines an antihistamine and a corticosteroid in a single formulation. By addressing both the allergic response and underlying nasal inflammation, Ryaltris® offers clinically meaningful differentiation in treatment of allergic rhinitis. Designed to support effective symptom control, convenience, and adherence, it reflects our patient-centric approach to respiratory innovation offering clinically meaningful differentiation for the management of seasonal and perennial allergies across global markets.
Our presence in Respiratory is defined by differentiated therapies developed through extensive and rigorous clinical trials.
Ryaltris
First-of-its-kind fixed dose nasal spray, our global
specialty product, commercialized in 46 countries
#1
Ryaltris ranked #1 in nasal sprays in LATAM
#1
In chronic respiratory care in Brazil
#2
In respiratory expectorants in Russia
#3
Position in India’s respiratory market
4
Respiratory brands ranked in the Top-300 in
the Indian Pharma Market
#1
Cough brand in India
#2
Nebulization brand in India
One of the Leading
Respiratory companies in South Africa
Dermatology - Foundational strength, reimagined through science
Dermatology is foundational to our identity and remains a core innovation focus. We began with a pioneering anti-fungal range of products and today our clinical focus spans across chronic and complex dermatological conditions including eczema, acne vulgaris, vitiligo, psoriasis, fungal infections, and scalp disorders. Backed by clinical rigour, dermatologist confidence, and a deep understanding of diverse skin types and treatment needs, today we are category leaders in multiple markets.
With Ichnos Glenmark Innovation (IGI), we have further strengthened our innovation-driven approach. Through our partnership with Almirall, our first-in-class IL-1RAP antagonist ISB 880, is now in Phase 2 of clinical development for the treatment of Hidradenitis Suppurativa. Our OX40 antagonist, ISB 830-KB, for atopic dermatitis is being advanced through our global partnership with Astria. These partnerships underscore the depth of our scientific rigor and innovation capabilities.With a scaled global presence, we remain focused on expanding access to high-quality dermatology therapies across age groups, climate conditions, and skin profiles, improving outcomes for millions of patients worldwide.
A flagship example of this innovation is WINLEVI®, a first-in-class topical androgen receptor inhibitor approved for the treatment of acne vulgaris. By targeting androgen signalling directly in the skin, WINLEVI® represents a novel, non-systemic approach to acne management, addressing an important gap in existing treatment options.
Advancing breakthroughs in Dermatology
Dermatology is one of Glenmark’s most established and strategically pivotal therapeutic areas, combining scientific depth, strong brand equity, and commercial scale.
4+ decades
Dermatology expertise
and category leadership
and innovation
120+
Products are part of our high-performing global franchise
15+
conditions addressed
covering chronic and complex
dermatological needs
